LifeStance Health Group (NASDAQ:LFST) Price Target Cut to $7.50 by Analysts at UBS Group

LifeStance Health Group (NASDAQ:LFST) had its target price decreased by UBS Group from $9.00 to $7.50 in a research note released on Thursday morning, Benzinga reports. UBS Group currently has a neutral rating on the stock.

Several other research analysts have also issued reports on the stock. Barclays lowered their price target on shares of LifeStance Health Group from $8.00 to $6.00 and set an underweight rating for the company in a report on Friday, August 9th. Morgan Stanley restated an overweight rating and issued a $10.00 target price on shares of LifeStance Health Group in a report on Monday, April 22nd. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, LifeStance Health Group has a consensus rating of Hold and an average price target of $8.25.

LifeStance Health Group Trading Down 1.4 %

Shares of LifeStance Health Group stock traded down $0.08 during trading on Thursday, hitting $5.76. The company’s stock had a trading volume of 634,679 shares, compared to its average volume of 1,510,417. The stock has a market cap of $2.20 billion, a price-to-earnings ratio of -12.17 and a beta of 1.20. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.18 and a quick ratio of 1.18. LifeStance Health Group has a 52 week low of $4.64 and a 52 week high of $9.20. The stock has a 50-day moving average price of $5.39 and a two-hundred day moving average price of $6.06.

LifeStance Health Group (NASDAQ:LFST) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.01. LifeStance Health Group had a negative return on equity of 11.92% and a negative net margin of 15.69%. The firm had revenue of $312.30 million for the quarter, compared to analyst estimates of $305.85 million. During the same quarter in the previous year, the company posted ($0.13) EPS. The business’s revenue was up 20.3% on a year-over-year basis. Equities research analysts anticipate that LifeStance Health Group will post -0.25 EPS for the current fiscal year.

Insider Activity

In related news, major shareholder Summit Partners Growth Equity sold 3,802,345 shares of the stock in a transaction on Friday, May 24th. The shares were sold at an average price of $5.89, for a total transaction of $22,395,812.05. Following the transaction, the insider now directly owns 41,932,358 shares of the company’s stock, valued at $246,981,588.62. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, major shareholder Summit Partners Growth Equity sold 3,802,345 shares of the business’s stock in a transaction that occurred on Friday, May 24th. The stock was sold at an average price of $5.89, for a total transaction of $22,395,812.05. Following the completion of the sale, the insider now owns 41,932,358 shares in the company, valued at $246,981,588.62. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Kevin Michael Mullins sold 85,093 shares of the business’s stock in a transaction on Tuesday, June 11th. The shares were sold at an average price of $5.53, for a total transaction of $470,564.29. Following the sale, the insider now owns 4,650,571 shares of the company’s stock, valued at approximately $25,717,657.63. The disclosure for this sale can be found here. Insiders sold 4,037,438 shares of company stock worth $23,647,876 in the last quarter. 6.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On LifeStance Health Group

Large investors have recently added to or reduced their stakes in the business. Brown Advisory Inc. raised its stake in shares of LifeStance Health Group by 25.9% in the fourth quarter. Brown Advisory Inc. now owns 5,158,980 shares of the company’s stock worth $40,395,000 after purchasing an additional 1,062,887 shares during the last quarter. Dimensional Fund Advisors LP raised its position in LifeStance Health Group by 82.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,016,452 shares of the company’s stock valued at $4,991,000 after buying an additional 457,930 shares during the last quarter. Magnetar Financial LLC purchased a new stake in LifeStance Health Group in the 2nd quarter valued at $762,000. TD Asset Management Inc bought a new position in LifeStance Health Group during the 2nd quarter valued at $623,000. Finally, Principal Financial Group Inc. raised its holdings in shares of LifeStance Health Group by 2.8% in the fourth quarter. Principal Financial Group Inc. now owns 4,006,344 shares of the company’s stock valued at $31,370,000 after purchasing an additional 110,457 shares during the last quarter. Institutional investors own 85.50% of the company’s stock.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.